3D Medicines (HKSE:01244) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01244 3D Medicines Inc HKSE:01244
47 GF Score
Price HK$2.27
GF Value HK$3.09
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is 3D Medicines Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

HKSE:01244
47GF Score
3D Medicines Inc HKSE:01244
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is 3D Medicines (HKSE:01244) Overvalued in 2026?

Based on GuruFocus' analysis, 3D Medicines stock appears to be undervalued. The current stock price of HK$2.27 is trading 26.7% below its estimated GF Value™ of HK$3.09. GuruFocus considers 3D Medicines to be Modestly Undervalued.

Key valuation signals for HKSE:01244:

  • Dividends Received:
  • GF Value™: HK$3.09 vs. price of HK$2.27 (26.7% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the HKSE:01244 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


3D Medicines Business Description

Address No. 3 and No. 5, Laiyang Road, Shandong Province, Shinan District, Qingdao, CHN
3D Medicines Inc is an investment holding company. The company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products.It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China. Its commercialized product is Envita.
47GF Score

Get the complete analysis for HKSE:01244

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.27
Price
HK$3.09
GF Value